The vaccines available today defend against many types (strains) of pneumococcal bacteria, but they don’t protect against all. That’s why we are researching if an investigational formulation of our pneumococcal vaccine can help protect against more strains.
What to expect#
- Your child will receive 1 dose of the study vaccine or a licensed pneumococcal vaccine called Prevnar 20®.
- Participation lasts about 6 months.
- There is no cost to participate.
Taking part in this clinical trial may help improve vaccine protection not only for your child, but also other children in the future.
Who can take part#
This study is enrolling healthy children and teens who:
- Are 15 to 23 months old and have received at least 2 prior doses of a pneumococcal vaccine, OR
- Are 2 to 17 years old and have received 0 to 4 prior doses of a pneumococcal vaccine,
Ready to learn more?#
For more information, contact the study team:
